Form 4: Tango Therapeutics Executive Executes Stock Option Plan
Statement of Changes in Beneficial Ownership
Adam Crystal, President of R&D at Tango Therapeutics, exercised options and sold 27,000 shares under a 10b5-1 plan.
Summary
- Adam Crystal, President of R&D at Tango Therapeutics, exercised stock options for 27,000 shares at a strike price of $5.20.
- Following the exercise, the reporting person sold the 27,000 shares in two tranches at weighted average prices of $22.252 and $23.0558.
- The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
- The reporting person retains beneficial ownership of 115,743 shares of common stock following these transactions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-established 10b5-1 plan, which is a routine administrative action for corporate insiders.
Positives
- The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sales were not based on sudden non-public information.
- The executive continues to hold a significant position of 115,743 shares, maintaining alignment with shareholder interests.
Negatives
- The transaction represents a divestment of equity by a key member of the R&D leadership team.
Risks
- Future stock price volatility may impact the value of remaining holdings.
- Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for biotech executives to manage personal liquidity and diversify portfolios, and is generally viewed as neutral by the market when pre-planned.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders in the biotechnology sector to avoid allegations of insider trading.
- The exercise and sale of vested options is consistent with typical executive compensation and liquidity management cycles observed in mid-cap biotech firms.
Stakeholder Impact
- Minimal impact expected as the transaction was pre-planned and disclosed in accordance with SEC regulations.
Next Steps
- Continued monitoring of future Form 4 filings for further insider activity.
Key Dates
| Date | Description |
|---|---|
| 2024-02-27 | Initial vesting date for the stock options exercised. |
| 2025-10-27 | Adoption date of the Rule 10b5-1 trading plan. |
| 2026-06-01 | Date of the earliest transaction (exercise and sale of shares). |
| 2026-06-03 | Date of filing. |
| 2033-03-01 | Expiration date of the stock options. |
Keywords
Tango Therapeutics, TNGX, Insider Trading, Form 4, Biotech, Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.